Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;49(1):26-33.
doi: 10.1111/jmp.12438. Epub 2019 Oct 1.

BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta)

Yanhui Cai  1 , Meagan A Watkins  2 , Fengtian Xue  3 , Yong Ai  3 , Huiming Cheng  3 , Cecily C Midkiff  2 , Xiaolei Wang  2 , Xavier Alvarez  2 , Adi Narayana Reddy Poli  4 , Joseph M Salvino  4 , Ronald S Veazey  2 , Luis J Montaner  1
Affiliations

BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta)

Yanhui Cai et al. J Med Primatol. 2020 Feb.

Abstract

Background: The BTB domain of B-cell lymphoma 6 (BCL6) protein was identified as a therapeutic target for B-cell lymphoma. This study compared the pharmacokinetics (PK) of the BCL6 BTB inhibitor (FX1) between mice and macaques, as well as evaluating its lymphoid suppressive effect in uninfected macaques with lymphoid hyperplasia.

Materials and methods: Eight uninfected adult Indian rhesus macaques (Macaca mulatta) were used in the study, four animals carrying lymphoid tissue hyperplasia. Plasma FX1 levels were measured by HPLC-MS/MS. Lymph node biopsies were used for H&E and immunohistochemistry staining, as well as mononuclear cell isolation for flow cytometry analysis.

Results: Inhibition of the BCL6 BTB domain with FX1 led to a reduction in the frequency of GC, Tfh CD4+ , and Tfh precursor cells, as well as resolving lymphoid hyperplasia, in rhesus macaques.

Conclusions: B-cell lymphoma 6 inhibition may represent a novel strategy to reduce hyperplastic lymphoid B-cell follicles and decrease Tfh cells.

Keywords: B-cell lymphoma 6; T follicular helper; germinal center reaction; lymphoid hyperplasia.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.. Pharmacokinetic of BCL6 BTB inhibitor (FX1) in uninfected rhesus macaques and mice.
(A) Schematic diagram of the experimental design. Two Indian rhesus macaques received one dose of FX1 at 25mg/kg S.Q. and then underwent five blood collection at 0, 2,4,6 and 24hr later. 18 CD-1 mice received on FX1 at 25mg/kg I.P. and then underwent six blood collections with each collection including three mice at 0.5, 2,4,6, 8 and 24hr later. Additional 3 CD-1 mice received vehicle were used for collecting blood at 24hr later as the negative control. (B) The plasma FX1 concentrations measured at 0, 0.5, 2, 4, 6, 8 and 24hr after one dose of FX1 injection were presented. (C) The FX1 exposure level in mice and macaques was calculated using the area under the curve (AUC) and presented. Mean and standard error were indicated in panel B and C.
Figure 2.
Figure 2.. BCL6 BTB inhibitor (FX1) treatment reduced the frequency of lymphoid Tfh CD4+ T cells and its precursor cells.
(A-B) Representative histogram (A) and summary (B) showing the frequency of CXCR5+CD4+ T cells in the lymph node of healthy control macaques, macaques with lymphoid hyperplasia, and those macaques with lymphoid hyperplasia receiving an 8-day course FX1 treatment (except 7-day course FX1 treatment for one animal receiving FX1 at 25mg/kg). (C) Representative flow plot for the frequency of CXCR5hiPD1hi Tfh CD4+ T cells and its precursor cells (CXCR5dimCD4+) in the lymph node of four healthy control macaques, macaques with lymphoid hyperplasia, and those macaques with lymphoid hyperplasia receiving an 7- or 8-day course FX1 treatment at 25mg/kg. (D-E) The frequency of Tfh (D) and Tfh CD4+ precursor cells (E) in lymph nodes from four macaques with lymphoid hyperplasia at baseline and 48hr after an 7- or 8-day course FX1 treatment, as well as four healthy control macaques. (F) Representative images for the lymph node biopsies from the same adult macaques with lymphoid hyperplasia before (left) and 48hr (right) after FX1 treatment (25mg/kg). Anti-CD3 (green), anti-CD68 (blue), and anti-BCL6 (red) are presented. Images were captured at 200x magnification.
Figure 3.
Figure 3.. BCL6 BTB inhibitor (FX1) treatment reduced lymphoid hyperplasia and Ki67+ T cells in the germinal center.
Lymph node biopsies were collected from four adult macaques exhibiting lymphoid hyperplasia at baseline and 48hr after an 8-day course FX1 treatment. (A-D) H&E staining of lymph node biopsies at baseline (A&B) and after (C&D) 10mg/kg (C) and 25mg/kg (D) FX1 treatment for an 8-day course are presented. (E) Representative images for H&E stained lymph node tissue sections from healthy rhesus macaques. Images were captured at 100x magnification; Germinal center areas are highlighted in each section (see black ovals). (F-I) Immunofluorescence staining of the lymph node biopsies from macaques with lymphoid hyperplasia before treatment (F&G) and after receiving BCL6 FX1 treatment at 10mg/kg (H) and 25mg/kg (I). (J) Higher mangnification of baseline (pre-treatment) images are shown for the expression of Ki67 in the germinal center T cells. The tissue sections were stained with anti-CD3 (green), anti-CD20 (blue), anti-Ki67 (red) and DAPI (grey). Images were captured at 400x magnification.
Figure 4.
Figure 4.. BCL6 BTB inhibition via FX1 treatment did not cause any systemic adverse effect in rhesus macaques with lymphoid hyperplasia.
(A) A schema for FX1 injection, blood collection, and lymph node biopsy sample collection in the study. (B) The frequency of immune response cells in the PBMC and lymph node were analyzed by flow cytometry and presented. (C) The frequency of T cell subsets [CD4+, CD8+, double positive (DP), double negative (DN)] in the PBMC and lymph node analyzed by flow cytometry were presented. (D) The body weight measured before and after FX1 treatment was presented. (E-F) The white blood cell counts (WBC) (E) and platelet (F) obtained by CBC analysis were presented. Note panel B lists color code for animal data shown in panels B-G.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cerchietti L, Melnick A. 2013. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol 6:343–345. - PMC - PubMed
    1. Huang F, Jin Y, Wei Y. 2016. MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6. Oncol Lett 11:2845–2850. - PMC - PubMed
    1. Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, Abbott J, Tam W, Du W, Leonard JP, Elemento O, Cerchietti L, Cierpicki T, Xue F, MacKerell AD Jr., Melnick AM. 2016. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest 126:3351–3362. - PMC - PubMed
    1. Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD Jr., Melnick AM. 2017. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clin Cancer Res 23:885–893. - PMC - PubMed
    1. Ueda C, Akasaka T, Ohno H. 2002. Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications. Leuk Lymphoma 43:1375–1381. - PubMed

Publication types

MeSH terms